GlassScriptPhysician profile
Mahsa Matloobi
NPI 1609101211
$5,806.46
in general payments reported to CMS, 2019-2025
49 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $452 · 2021: $705 · 2022: $1,098 · 2023: $1,217 · 2024: $1,048 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290 · Education: $85.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.19 |
| Education | $85.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $406.69 | 2019-2024 | |
| Biogen, INC. | $322.48 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Amgen INC. | $310.32 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $288.98 | 2020-2025 | Ingrezza |
| Pfizer INC. | $260.78 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $237.58 | 2020-2024 | Ultomiris, Soliris |
| Ucb, INC. | $232.34 | 2024-2025 | Rystiggo, Briviact, Nayzilam |
| Genentech USA, INC. | $214.30 | 2019-2023 | Ocrevus |
| Acadia Pharmaceuticals INC | $173.39 | 2021-2025 | Nuplazid |
| Sk Life Science, INC. | $159.67 | 2022-2024 | |
| Lilly USA, LLC | $146.89 | 2019-2025 | Amyvid, Kisunla |
| Alnylam Pharmaceuticals INC. | $145.61 | 2022-2025 | Amvuttra |
| Biohaven Pharmaceutical Holding Company LTD. | $134.71 | 2022 | |
| Argenx US, INC. | $102.60 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahsa Matloobi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.